Pangea Bio
Pangea Bio, a biotechnology research company founded in 2021 and headquartered in London, focuses on drug discovery for neurological disorders using AI and natural substances.
Company Overview
Pangea Bio, founded in 2021 and headquartered in London, GB, operates within the Biotechnology Research industry. Describing itself as 'Drug discovery inspired by nature, powered by AI,' the company focuses on creating medicines for neurological and neuropsychiatric disorders. It has a team size of 33, categorizing it as a small business. Pangea Bio is committed to the highest ESG standards and is a Certified B Corporation.
Services
Pangea Bio specializes in drug discovery and development for neurological disorders. Its efforts are driven by the PangeAI™ discovery platform, which accelerates the identification of novel therapeutics from plants and other life forms. The company utilizes AI to study natural compounds and leverage traditional knowledge of their therapeutic potential. This process includes building a scalable pipeline of nature-inspired drugs for the Central Nervous System (CNS).
Research and Development
The company's lead R&D program focuses on Central Nervous System (CNS) disorders. The lead asset, OT-003, inspired by a natural compound, shows compelling efficacy across neurological disease models. Phase 1 studies for OT-003 are planned to start in 2024, with a target initiation in Q1 2025. Pangea Bio is also developing a portfolio of TrkB-activating compounds to treat various neurological disorders.
Strategic Collaborations
Pangea Bio has joined forces with leading academic institutions in Europe through the ETHCSTWIN Initiative. The company has also been accepted into the One Mind Accelerator Program and the Einstein Biotech Innovation Program. These collaborations aim to enhance Pangea Bio's research capabilities and expedite the development of innovative therapeutics.
Environmental and Social Responsibility
Pangea Bio is committed to meeting the highest standards of social and environmental impact, exemplified by its Certified B Corporation status. The company adheres to the Nagoya Protocol on Access and Benefit Sharing. Additionally, it is setting up the non-profit PangeACT to support efforts in knowledge preservation, environmental protection, and education.